Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 3, 2026Expert Opinion on Therapeutic Patents

Novel small-molecule T-type calcium channel blockers advance to clinical trials for non-essential tremor.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Extensive efforts have been made to identify and develop novel small organic compounds blocking T-type calcium channels, leading to numerous recent patents.

Design

Review of literature and patent databases (2018 to 2025)

Key result

Recent advances from 2018 to 2025 highlight the development of novel small organic compounds targeting T-type calcium channels, with some advancing to clinical trials for non-essential tremor.

Authors

YTYasinalli TamboliLFLaurent FerronGZGerald W. Zamponi

Discussion

Loading...

Member takes

Overview

Patent review maps emerging T-type channel blockers; leaves open clinical translation for epilepsy, pain, and tremor.

Key Points

  • This review aims to summarize recent advances in T-type calcium channel blockers and their potential therapeutic applications.
  • Reviewed literature and patent databases from 2018 to 2025
  • Categorized patented small organic molecules by chemical scaffold
  • Analyzed preclinical and clinical developments of T-type calcium channel blockers
  • New T-type calcium channel blockers are advancing into clinical trials
  • Some pan T-type channel blockers have adverse effects in non-essential tremor trials
  • Subtype-specific inhibitors may reduce adverse effects compared to pan blockers

Structured PICO

I
Intervention
T-type calcium channel blockers (patented organic small molecules)

This review highlights recent advances in T-type calcium channel blockers, emphasizing the potential need for subtype-specific inhibitors to avoid adverse effects seen with pan-blockers.

Cite This Study

Tamboli et al. (2026) conducted a review in Epilepsy, pain, and non-essential tremor. T-type calcium channel blockers was evaluated. Recent advances from 2018 to 2025 highlight the development of novel small organic compounds targeting T-type calcium channels, with some advancing to clinical trials for non-essential tremor.

synapsesocial.com/papers/6a70404875942ff7265e52echttps://doi.org/10.1080/13543776.2026.2713553
View Full Paper
Ask AI
Bookmark
Share